The persistent scarcity of furosemide 20 mg and 40 mg—a cornerstone diuretic medication used to manage conditions such as heart failure, renal impairment, and hepatic edema—has entered a critical phase. As of mid-November 2026, the French National Agency for the Safety of Medicines and Health Products (ANSM) has confirmed that supply chain disruptions are expected to continue well into 2027. To mitigate the risks of treatment interruption for patients relying on Lasilix and its various generic counterparts, the agency has issued a formal authorization allowing pharmacists to dispense magistral preparations, marking a significant intervention in standard pharmaceutical distribution protocols.

Chronology of the Supply Crisis

The current disruption is not a sudden development but the culmination of months of manufacturing and distribution pressures. The situation first garnered national attention in early October 2026, when pharmacists across France began reporting significant difficulty in securing standard stocks of oral furosemide. By October 8, 2026, the ANSM had issued its initial guidance, urging healthcare providers to prioritize existing patients and limit the initiation of new treatments.

Despite these early interventions, the market failed to stabilize. By November 19, 2026, the ANSM provided a sobering update: the shortage in community pharmacies remains severe, with no definitive timeline provided by manufacturers for the restoration of normal supply levels. While the hospital sector—often supplied through different logistics channels—remains largely unaffected for the time being, the burden has fallen squarely on the shoulders of retail pharmacies and the patients they serve. For the French overseas territories (DROM-COM), the ANSM has issued specific mandates to laboratories to maintain supply lines through established local routes, acknowledging the unique logistical challenges inherent in those regions.

Strategic Interventions and Regulatory Measures

The decision to authorize magistral preparations is the latest in a series of measures designed to prevent a public health emergency. In addition to this, the ANSM has implemented a policy of strictly prohibiting direct sales from manufacturers to third parties, ensuring that available stock is channeled primarily toward the retail pharmacy network to satisfy patient prescriptions.

The authorization for magistral preparations—drugs compounded by pharmacists specifically for a patient—is a reactive measure intended to bypass the reliance on standardized industrial manufacturing. As of November 10, 2026, the ANSM has granted pharmacists the authority to dispense these compounded capsules without requiring a new prescription, provided the original medication is unavailable. This policy represents a pragmatic shift, allowing the pharmaceutical supply chain to regain some level of flexibility during a period of sustained volatility.

Tension en furosémide : l'ANSM autorise le recours aux préparations magistrales

Technical Guidelines for Pharmacists

Pharmacists are now authorized to prepare two specific dosages of furosemide (20 mg and 40 mg) in capsule form. This process involves strict adherence to standardized compounding practices to ensure patient safety and therapeutic equivalence. The preparations are available in three distinct quantity tiers, designed to align with typical chronic care needs.

Crucially, the ANSM has mandated that every patient receiving a magistral preparation must be provided with a specific information sheet. This document serves as a bridge for patients who are accustomed to commercial tablets, explaining the differences in physical appearance and the importance of adhering to the prescribed regimen despite the shift in delivery format.

Furthermore, the financial framework for these preparations has been standardized. To ensure that patients are not financially penalized by the shift to magistral alternatives, the ANSM, in coordination with the national health insurance system, has established a fixed pricing structure. These prices, which include both the cost of the raw active pharmaceutical ingredient and the labor costs associated with compounding (dispensation fees), are reimbursed at the standard 65% rate, maintaining continuity with the coverage level of traditional furosemide products.

Clinical Management and Treatment Restrictions

The ANSM remains firm on its directive regarding the initiation of new treatments. Despite the availability of magistral alternatives, the agency emphasizes that the focus must remain on maintaining existing therapeutic protocols rather than expanding the user base of a medication that is currently in short supply.

For patients requiring treatment for edema—whether of cardiac, renal, or hepatic origin—or for hypertension in the context of chronic kidney disease, physicians are advised to exercise extreme clinical judgment. The agency’s recommendations for medical practitioners include:

  • Prioritizing the supply for patients with the most urgent clinical needs.
  • Evaluating the possibility of therapeutic alternatives where clinically appropriate, provided that such alternatives are not themselves in a state of shortage.
  • Conducting frequent monitoring to ensure that the transition to magistral preparations does not result in therapeutic failure or adverse reactions.

Broader Implications for the Pharmaceutical Industry

The ongoing furosemide shortage highlights a structural vulnerability in the European pharmaceutical market. Furosemide, a generic, low-cost medication, is frequently subject to "just-in-time" supply chains that leave little room for error. When a single manufacturing site experiences a delay—whether due to raw material procurement issues, quality control hurdles, or logistics failures—the downstream impact is immediate and profound.

Tension en furosémide : l'ANSM autorise le recours aux préparations magistrales

Industry analysts suggest that the duration of this crisis, projected to last through 2027, indicates that the underlying causes are not merely transient. Factors such as the consolidation of manufacturing sites, the reliance on a limited number of active pharmaceutical ingredient (API) suppliers, and increased demand in other global markets have contributed to a strained ecosystem.

From a public health perspective, the reliance on magistral preparations is an effective, albeit expensive and labor-intensive, temporary fix. While it prevents patient harm, it places an significant workload burden on community pharmacies, which must now pivot from being dispensers of mass-manufactured goods to being active compounders. This shift raises questions about the long-term sustainability of such solutions, particularly if supply chain instability becomes a recurring theme in the coming years.

Future Outlook and Patient Considerations

Patients currently prescribed furosemide are advised to maintain open communication with their pharmacists and primary care physicians. While the authorization of magistral preparations provides a pathway for treatment continuity, patients should be prepared for potential adjustments in their prescription cycles.

As the industry looks toward 2027, the focus will likely remain on diversifying the supply chain and increasing the transparency of stock levels. The ANSM’s proactive stance in issuing clear directives—including the detailed tables regarding dosage equivalence and reimbursement—serves as a template for how regulatory bodies may handle future drug shortages. However, the reliance on these contingency measures is a reminder that the stability of essential medicines remains a critical challenge for modern healthcare systems.

As of late 2026, no clear "end date" for the shortage has been established. The situation remains fluid, and the ANSM continues to monitor the production capacity of key pharmaceutical stakeholders. Patients are encouraged to consult the official VIDAL or ANSM portals for real-time updates regarding availability, ensuring that they remain informed as the situation evolves throughout the coming months. The priority remains clear: protecting the health of the patient population while navigating a global supply chain landscape that is increasingly prone to significant, long-term disruptions.

SanteNews

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.